Literature DB >> 26488745

Middle East Respiratory Syndrome in 3 Persons, South Korea, 2015.

Jeong-Sun Yang, SungHan Park, You-Jin Kim, Hae Ji Kang, Hak Kim, Young Woo Han, Han Saem Lee, Dae-Won Kim, A-Reum Kim, Deok Rim Heo, Joo Ae Kim, Su Jin Kim, Jeong-Gu Nam, Hee-Dong Jung, Hyang-Min Cheong, Kisoon Kim, Joo-Shil Lee, Sung Soon Kim.   

Abstract

In May 2015, Middle East respiratory syndrome coronavirus infection was laboratory confirmed in South Korea. Patients were a man who had visited the Middle East, his wife, and a man who shared a hospital room with the index patient. Rapid laboratory confirmation will facilitate subsequent prevention and control for imported cases.

Entities:  

Keywords:  MERS; MERS-CoV; Middle East respiratory syndrome; South Korea; respiratory infections; viruses

Mesh:

Year:  2015        PMID: 26488745      PMCID: PMC4622265          DOI: 10.3201/eid2111.151016

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Middle East respiratory syndrome (MERS) is characterized by mild-to-severe respiratory distress and is caused by a novel coronavirus (MERS-CoV) (). Since its first identification in 2012, MERS-CoV infection has been reported for 1,413 persons from 26 countries; case-fatality rate is 40.92% (). We describe an outbreak comprising 3 laboratory-confirmed cases of MERS-CoV infection in South Korea (–).

The Study

In accordance with national MERS control guidelines in South Korea (), specimens are collected from hospitalized patients suspected of having MERS on the basis of epidemiologic history linked to the Middle East; these specimens are then transferred to the Korea National Institute of Health for examination. The index patient, a 68-year-old man engaged in farming-related business, reported that he had traveled to Bahrain on April 24, 2015, the United Arab Emirates on April 29–30, Saudi Arabia on May 1–2, and Qatar on May 2–3 before returning to South Korea on May 4 (Figure 1). While in these countries, he was not exposed to any patients, health care facilities, or animals (including camels and bats) or their excreta. On May 11, the patient experienced chills and a fever (>37°C), and an allopathic medicine was prescribed when he first visited a local clinic. However, his symptoms worsened (temperature >38°C, myalgia, cough, and dyspnea), and after he had visited 4 hospitals (hospitals A–D, in or around Seoul), he was admitted to a general hospital (hospital D, Seoul, South Korea) on May 18. A nasopharyngeal aspiration specimen was collected for MERS-CoV laboratory testing on May 19.
Figure 1

Timeline of events for patients infected with Middle East respiratory syndrome coronavirus (MERS-CoV). The laboratory diagnostic methods used for molecular detection of MERS-CoV RNA were multiplex MERS-CoV real-time reverse transcription PCRs targeting an upstream MERS-CoV envelope protein gene and an open reading frame 1a gene (,). KSA, Kingdom of Saudi Arabia; UAE, United Arab Emirates.

Timeline of events for patients infected with Middle East respiratory syndrome coronavirus (MERS-CoV). The laboratory diagnostic methods used for molecular detection of MERS-CoV RNA were multiplex MERS-CoV real-time reverse transcription PCRs targeting an upstream MERS-CoV envelope protein gene and an open reading frame 1a gene (,). KSA, Kingdom of Saudi Arabia; UAE, United Arab Emirates. Sputum samples from 2 persons who had been in contact with the index patient were also tested for MERS-CoV. Patient 2 was the 63-year-old wife of the index patient; she had had physical contact with him while caring for him during the 3 days of hospitalization. Fever (38°C) and slight oliguria developed in patient 2 on May 19. The other contact, patient 3, was a 78-year-old man who had chronic obstructive pulmonary disease, asthma, and cholangiocarcinoma and who had shared a hospital room with the index patient and had been within 2 meters from him for 4 hours on May 16. Fever (37.8°C) and respiratory symptoms developed in patient 3 on May 20. In the hospital room, the index patient did not undergo any aerosol-generating procedures, but a severe cough developed. The same health care workers cared for the index patient and patient 3. Laboratory diagnostic methods were performed according to World Health Organization guidelines for molecular detection of MERS-CoV (–). To check for contamination derived from the positive control, we designed and synthesized the MERS-CoV real-time reverse transcription PCR (rRT-PCR)–positive transcripts for an upstream MERS-CoV envelope protein gene (upE) and the open reading frame 1a (ORF1a) gene containing 50 bp of a foreign gene (centipede). Initially, nasopharyngeal samples from the index patient were positive for MERS-CoV by multiplex rRT-PCR. Sputum samples from patients 2 and 3 were also positive, supporting a diagnosis of MERS-CoV infection. Multiplex rRT-PCR results for upE and ORF1a were positive (Table 1). According to rRT-PCR, the respiratory samples from the 3 patients were negative for 5 other human coronaviruses (SARS-CoV and human CoV-229E, -OC43, -NL63, and -HKU1) and 7 viruses that cause acute respiratory infection (influenza virus A and B; human adenovirus; bocavirus; human parainfluenza virus types 1, 2, and 3; respiratory syncytial virus A and B; human rhinovirus; human metapneumovirus).
Table 1

Real-time reverse transcription PCR results for 2 patients infected with Middle East respiratory syndrome coronavirus, South Korea, 2015*

SampleIndex patient (day 9 after illness onset)
Wife of index patient (day 2 after illness onset)
upE, CtORF1a, CtupE, CtORF1a, Ct
Sputum18.6119.3226.2326.63
Nasal swab29.3429.58ND36.64
Nasopharyngeal aspirate29.3531.45NTNT
Serum34.8135.50NDND
UrineNDND34.34ND

*Ct, cycle threshold; ND, not detected; NT, not tested; ORF1a, open reading frame 1a gene; upE, upstream envelope protein gene.

*Ct, cycle threshold; ND, not detected; NT, not tested; ORF1a, open reading frame 1a gene; upE, upstream envelope protein gene. For the index patient, MERS-CoV RNA was detectable in sputum, throat swab, and serum samples but not in a urine sample collected 9 days after symptom onset (Table 1). The viral load, indicated by cycle threshold values, was high in the lower respiratory tract sample but almost undetectable in the throat swab and serum samples. After sequential sampling repeated every 2–5 days, MERS-CoV RNA was detected in sputum until 44 days after symptom onset, although viral RNA was inconsistently detected and patterns of viral load fluctuated (Table 2). Other than initial fever (>37°C), clinical features differed for all 3 patients. The index patient had respiratory symptoms with cough, dyspnea, and myalgia. Patient 2 did not have a relevant medical history and showed mild symptoms. Patient 3 had underlying concurrent conditions and died 16 days after confirmation of MERS-CoV infection (Figure 1).
Table 2

Real-time reverse transcription PCR results for sputum samples serially collected from 3 patients infected with Middle East respiratory syndrome coronavirus, South Korea, 2015*

DatePatient 1 (index patient)
Patient 2†
Patient 3‡
Days after illness onsetupE, CtORF1a, CtDays after illness onsetupE, CtORF1a, CtDays after illness onsetupE, CtORF1a, Ct
May 20918.6119.32226.2326.63128.1028.65
May 221125.2425.67535.5335.10324.6725.04
May 251426.4827.991125.2026.10526.3725.53
May 281731.2332.051432.5834.808ND35.94
May 312036.94ND17NDND1126.3028.01
Jun 424ND36.2718NDND14NDND
Jun 62633.9236.7019Discharged15Died
Jun 82936.50ND
Jun 93036.9037.46
Jun 1233NDND
Jun1536NDND
Jun 163735.46ND
Jun 1738NDND
Jun 2243NDND
Jun 234432.9736.31
Jun 2647NDND
Jun 2950NDND
Jun 3051NDND

*Ct, cycle threshold; ND, not detected; ORF1a, open reading frame 1a gene; upE, upstream envelope protein gene. Blank cells indicate not applicable. 
†Wife of index patient.
‡Shared hospital room with index patient.

*Ct, cycle threshold; ND, not detected; ORF1a, open reading frame 1a gene; upE, upstream envelope protein gene. Blank cells indicate not applicable. 
†Wife of index patient.
‡Shared hospital room with index patient. Virus isolation on Vero cells was attempted for each respiratory specimen from the 3 patients. The culture supernatant after inoculation was serially assessed for virus growth by using rRT-PCR and was used for blind passages every 3–7 days after inoculation. After 3 blind passages, cytopathic effect was observed, and we isolated the MERS-CoV strain from South Korea (KOR/KNIH/002_05_2015) from the Vero cells after inoculation by using the sputum from patient 2. We constructed a phylogenetic tree by using the general time reversible plus gamma model of the RAxML version 8.8.0 software () and FigTree version 1.4.2 (http://tree.bio.ed.ac.uk/software/figtree) and by using complete genomes of the MERS-CoV isolate from South Korea (GenBank accession no. KT029139) and 67 reference MERS-CoVs (Figure 2).
Figure 2

Phylogenetic tree comparing complete genome nucleotide sequences of Middle East respiratory syndrome coronavirus (MERS-CoV) isolate from South Korea (KOR/KNIH/002_05_2015) with those of 67 reference MERS-CoVs (GenBank database). The tree was constructed by using the general time reversible plus gamma model of RAxML version 8.8.0 software () and visualized by using FigTree version 1.4.2 (http://tree.bio.ed.ac.uk/software/figtree). RAxML bootstrap values (1,000 replicates) are shown above the branches. Bootstrap values >75 are shown on the branches. The MERS-CoV strain from South Korea is shown in gray. National Center for Biotechnology Information accession numbers are shown before each taxon name. The unit of branch length is the number of substitutions per site. Scale bar indicates 4 × 10–4 nucleotide substitutions per site.

Phylogenetic tree comparing complete genome nucleotide sequences of Middle East respiratory syndrome coronavirus (MERS-CoV) isolate from South Korea (KOR/KNIH/002_05_2015) with those of 67 reference MERS-CoVs (GenBank database). The tree was constructed by using the general time reversible plus gamma model of RAxML version 8.8.0 software () and visualized by using FigTree version 1.4.2 (http://tree.bio.ed.ac.uk/software/figtree). RAxML bootstrap values (1,000 replicates) are shown above the branches. Bootstrap values >75 are shown on the branches. The MERS-CoV strain from South Korea is shown in gray. National Center for Biotechnology Information accession numbers are shown before each taxon name. The unit of branch length is the number of substitutions per site. Scale bar indicates 4 × 10–4 nucleotide substitutions per site.

Conclusions

Because, to our knowledge, cases of MERS-CoV infection in South Korea have not been reported, we had to establish laboratory testing protocols to overcome vulnerabilities in the absence of appropriate epidemiologic support (i.e., generate positive controls to check for contamination and repeat testing). Positive controls containing foreign genes have been generated to check for laboratory contamination. For patients with an unclear exposure history (such as the index patient) and for patients with short exposure durations and unusual clinical symptoms (such as patients 2 and 3), it would be useful if the positive results of rRT-PCR could be confirmed through agarose gel electrophoresis to exclude contamination from the positive control (,). The index patient had no history of potential exposure to camels, bats, or their excreta; to symptomatic persons; or to health care workers during his trip to the Middle East, including Saudi Arabia. Although the source of infection for the index patient is unclear, phylogenetic analysis of the whole viral genome showed that the isolate from South Korea was closely related to the MERS-CoV strains isolated in Saudi Arabia in 2015. Because the index patient initially concealed his travel history to Saudi Arabia, United Arab Emirates and Qatar, MERS-CoV infection was not considered and the patient was not isolated until MERS-CoV infection was suspected 7 days after symptom onset. Meanwhile, other patients and health care workers had multiple opportunities for exposure to the index patient (–). The 2 contacts reported here had each been exposed to the index patient. Patient 3 was probably infected via droplet transmission in the hospital room. The hospital room, originally built for 6 persons, had been divided into 2 rooms and lacked ventilation. Furthermore, an air conditioning unit cycled the air in the room with the door and window closed. Thus, poor ventilation might have played a major role in droplet transmission. Detection of MERS-CoV RNA in the respiratory tract varies up to day 33 (–). In this study, virus was detected in the respiratory tract, inconsistently, for up to 44 days. Development of effective preventive measures for the MERS-CoV prevention will require systemic and prospective studies associated with viral shedding and use of specimens in addition to those obtained from the respiratory tract to define the kinetics of MERS-CoV. Rapid detection of MERS-CoV, using multiplex rRT-PCR to detect upE and ORF1a genes, would be helpful for countries outside the Arabian Peninsula.
  10 in total

1.  Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections.

Authors:  V M Corman; M A Müller; U Costabel; J Timm; T Binger; B Meyer; P Kreher; E Lattwein; M Eschbach-Bludau; A Nitsche; T Bleicker; O Landt; B Schweiger; J F Drexler; A D Osterhaus; B L Haagmans; U Dittmer; F Bonin; T Wolff; C Drosten
Journal:  Euro Surveill       Date:  2012-12-06

2.  Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015.

Authors:  B J Cowling; M Park; V J Fang; P Wu; G M Leung; J T Wu
Journal:  Euro Surveill       Date:  2015-06-25

3.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.

Authors:  Ali M Zaki; Sander van Boheemen; Theo M Bestebroer; Albert D M E Osterhaus; Ron A M Fouchier
Journal:  N Engl J Med       Date:  2012-10-17       Impact factor: 91.245

4.  Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction.

Authors:  V M Corman; I Eckerle; T Bleicker; A Zaki; O Landt; M Eschbach-Bludau; S van Boheemen; R Gopal; M Ballhause; T M Bestebroer; D Muth; M A Müller; J F Drexler; M Zambon; A D Osterhaus; R M Fouchier; C Drosten
Journal:  Euro Surveill       Date:  2012-09-27

5.  RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies.

Authors:  Alexandros Stamatakis
Journal:  Bioinformatics       Date:  2014-01-21       Impact factor: 6.937

6.  An Unexpected Outbreak of Middle East Respiratory Syndrome Coronavirus Infection in the Republic of Korea, 2015.

Authors: 
Journal:  Infect Chemother       Date:  2015-06-30

7.  Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection.

Authors:  Christian Drosten; Michael Seilmaier; Victor M Corman; Wulf Hartmann; Gregor Scheible; Stefan Sack; Wolfgang Guggemos; Rene Kallies; Doreen Muth; Sandra Junglen; Marcel A Müller; Walter Haas; Hana Guberina; Tim Röhnisch; Monika Schmid-Wendtner; Souhaib Aldabbagh; Ulf Dittmer; Hermann Gold; Petra Graf; Frank Bonin; Andrew Rambaut; Clemens-Martin Wendtner
Journal:  Lancet Infect Dis       Date:  2013-06-17       Impact factor: 25.071

8.  Probable transmission chains of Middle East respiratory syndrome coronavirus and the multiple generations of secondary infection in South Korea.

Authors:  Shui Shan Lee; Ngai Sze Wong
Journal:  Int J Infect Dis       Date:  2015-07-26       Impact factor: 3.623

9.  Kinetics and pattern of viral excretion in biological specimens of two MERS-CoV cases.

Authors:  J Poissy; A Goffard; E Parmentier-Decrucq; R Favory; M Kauv; E Kipnis; D Mathieu; S van der Werf; B Guery
Journal:  J Clin Virol       Date:  2014-07-12       Impact factor: 3.168

10.  Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen.

Authors:  Nikolaos Spanakis; Sotirios Tsiodras; Bart L Haagmans; V Stalin Raj; Kostantinos Pontikis; Antonia Koutsoukou; Nikolaos G Koulouris; Albert D M E Osterhaus; Marion P G Koopmans; Athanassios Tsakris
Journal:  Int J Antimicrob Agents       Date:  2014-09-18       Impact factor: 5.283

  10 in total
  14 in total

Review 1.  Middle East Respiratory Syndrome (MERS) Virus-Pathophysiological Axis and the Current Treatment Strategies.

Authors:  Abdullah M Alnuqaydan; Abdulmajeed G Almutary; Arulmalar Sukamaran; Brian Tay Wei Yang; Xiao Ting Lee; Wei Xuan Lim; Yee Min Ng; Rania Ibrahim; Thiviya Darmarajan; Satheeshkumar Nanjappan; Jestin Chellian; Mayuren Candasamy; Thiagarajan Madheswaran; Ankur Sharma; Harish Dureja; Parteek Prasher; Nitin Verma; Deepak Kumar; Kishneth Palaniveloo; Dheeraj Bisht; Gaurav Gupta; Jyotsana R Madan; Sachin Kumar Singh; Niraj Kumar Jha; Kamal Dua; Dinesh Kumar Chellappan
Journal:  AAPS PharmSciTech       Date:  2021-06-08       Impact factor: 3.246

Review 2.  Strategy and technology to prevent hospital-acquired infections: Lessons from SARS, Ebola, and MERS in Asia and West Africa.

Authors:  Sanjeewa Jayachandra Rajakaruna; Wen-Bin Liu; Yi-Bo Ding; Guang-Wen Cao
Journal:  Mil Med Res       Date:  2017-10-27

Review 3.  Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea.

Authors:  Myoung-Don Oh; Wan Beom Park; Sang-Won Park; Pyoeng Gyun Choe; Ji Hwan Bang; Kyoung-Ho Song; Eu Suk Kim; Hong Bin Kim; Nam Joong Kim
Journal:  Korean J Intern Med       Date:  2018-02-27       Impact factor: 2.884

4.  Sequential Emergence and Wide Spread of Neutralization Escape Middle East Respiratory Syndrome Coronavirus Mutants, South Korea, 2015.

Authors:  Yeon-Sook Kim; Abdimadiyeva Aigerim; Uni Park; Yuri Kim; Ji-Young Rhee; Jae-Phil Choi; Wan Beom Park; Sang Won Park; Yeonjae Kim; Dong-Gyun Lim; Kyung-Soo Inn; Eung-Soo Hwang; Myung-Sik Choi; Hyoung-Shik Shin; Nam-Hyuk Cho
Journal:  Emerg Infect Dis       Date:  2019-06-17       Impact factor: 6.883

Review 5.  Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development.

Authors:  A Volz; G Sutter
Journal:  Adv Virus Res       Date:  2016-08-01       Impact factor: 9.937

6.  Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity.

Authors:  Chan-Ki Min; Shinhye Cheon; Na-Young Ha; Kyung Mok Sohn; Yuri Kim; Abdimadiyeva Aigerim; Hyun Mu Shin; Ji-Yeob Choi; Kyung-Soo Inn; Jin-Hwan Kim; Jae Young Moon; Myung-Sik Choi; Nam-Hyuk Cho; Yeon-Sook Kim
Journal:  Sci Rep       Date:  2016-05-05       Impact factor: 4.379

7.  Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea.

Authors:  Wan Beom Park; Ranawaka A P M Perera; Pyoeng Gyun Choe; Eric H Y Lau; Seong Jin Choi; June Young Chun; Hong Sang Oh; Kyoung-Ho Song; Ji Hwan Bang; Eu Suk Kim; Hong Bin Kim; Sang Won Park; Nam Joong Kim; Leo Lit Man Poon; Malik Peiris; Myoung-Don Oh
Journal:  Emerg Infect Dis       Date:  2015-12       Impact factor: 6.883

8.  Comparison of confirmed COVID-19 with SARS and MERS cases - Clinical characteristics, laboratory findings, radiographic signs and outcomes: A systematic review and meta-analysis.

Authors:  Ali Pormohammad; Saied Ghorbani; Alireza Khatami; Rana Farzi; Behzad Baradaran; Diana L Turner; Raymond J Turner; Nathan C Bahr; Juan-Pablo Idrovo
Journal:  Rev Med Virol       Date:  2020-06-05       Impact factor: 11.043

9.  A Middle East respiratory syndrome screening clinic for health care personnel during the 2015 Middle East respiratory syndrome outbreak in South Korea: A single-center experience.

Authors:  Ji Yeon Lee; Gayeon Kim; Dong-Gyun Lim; Hyeon-Gun Jee; Yunyoung Jang; Joon-Sung Joh; Ina Jeong; Yeonjae Kim; Eunhee Kim; Bum Sik Chin
Journal:  Am J Infect Control       Date:  2017-11-16       Impact factor: 2.918

10.  Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein.

Authors:  Junghyun Goo; Yuji Jeong; Young-Shin Park; Eunji Yang; Dae-Im Jung; Semi Rho; Uni Park; Hyeyeong Sung; Pil-Gu Park; Jung-Ah Choi; Sang Hwan Seo; Nam Hyuck Cho; Hyeja Lee; Jae Myun Lee; Jae-Ouk Kim; Manki Song
Journal:  Virus Res       Date:  2020-01-13       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.